MOD3 Pharma is attending RDD Europe 2025 in Lisbon, Portugal, 6-9 May.

Schedule a meeting with Paul Shields and Sana Hosseini or catch them by the MOD3 Pharma booth at the conference. The team is eager to discuss how MOD3 Pharma can be your CATALYST TO CLINIC. 

 

At MOD3 Pharma, our experts are ready to support your OINDPs through early clinical trials, Phase 1 and Phase 2. Our team can guide you through the development of OINDPs, with the end in mind. Our services address the needs of organizations requiring early-phase clinical supplies for single-dose powder and liquid nasal systems, as well as bi-dose and multi-dose nasal devices.